Cybin To Acquire Small Pharma Inc.; Small Pharma Shareholders Will Receive 0.2409 Common Shares In The Capital Of Cybin; Exchange Ratio Implies Consideration Of ~$0.10 Per Small Pharma Share
Portfolio Pulse from Happy Mohamed
Cybin Inc. (NYSE:CYBN) is set to acquire Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) in an all-share transaction. Small Pharma shareholders will receive 0.2409 common shares in Cybin for each Small Pharma share held, implying a consideration of approximately $0.10 per Small Pharma share. The combined entity will hold the most extensive intellectual property portfolio in the psychedelic drug development sector, with 28 granted patents and 158 pending. The acquisition is expected to close in late October 2023.
August 28, 2023 | 2:52 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Small Pharma's shareholders will receive 0.2409 common shares in Cybin for each Small Pharma share held, implying a consideration of approximately $0.10 per Small Pharma share. This could potentially impact the stock price of Small Pharma.
The acquisition deal implies a consideration of approximately $0.10 per Small Pharma share. This could potentially impact the stock price of Small Pharma, although the direction of the impact is uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Cybin's acquisition of Small Pharma could potentially boost its stock as it expands its portfolio and strengthens its position in the psychedelic therapeutics sector.
The acquisition of Small Pharma will significantly expand Cybin's portfolio and strengthen its position in the psychedelic therapeutics sector. This could potentially attract more investors, leading to a rise in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100